Key facts
- Notable investors include ALP Professional Services, Argentil Capital Management, Argentil Capital Managment, Healthcap Africa.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Sygen
- ·The full record, as it builds
Funding rounds
No funding rounds for Sygen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sygen
Manufacturer of pharmaceutical drugs intended to make drugs affordable, available, and easily accessible to the middle and lower-income demographic of the economy. The company's product line encompasses analgesics, antidiabetics, antifungals, antispasmodics, cough medications, and hematinic drugs, enabling customers to lead healthier lives.
- Sector
- Healthcare
- HQ
- Lagos, Nigeria
- Founded
- 2019
- Employees
- 120
- Website
- sygenpharma.com/
- Ownership
- Privately Held (backing)
Sygen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sygen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sygen in its N-PORT filings yet. We sweep new filings monthly.